Clinical trials: Carcinomas
Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants…
- Trial name
- NCT06212752
- Testing
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin
- Where
- 18 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to…
- Trial name
- ATILA (NCT03916458)
- Where
- 31 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Pfizer
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
NAXIVA is a study of axitinib in patients with metastatic and non-metastatic renal cell carcinoma with venous invasion. Patients will be given axitinib (twice daily) for 8 weeks (at an escalated dose) and the response of the…
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Non-metastatic Renal Cell Carcinoma
- Trial name
- NAXIVA (NCT03494816)
- Testing
- Axitinib Oral Tablet
- Where
- 7 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Scottish Clinical Trials Research Unit
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Non-small Cell Lung Cancer, NSCLC
Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).
- Trial name
- NCT04822298
- Testing
- AMG 160
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- Amgen
Kidney Neoplasms, Carcinoma, Renal Cell
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).
- Trial name
- NCT00282048
- Testing
- AG-013736 (axitinib)
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pfizer
Peritoneal Cancer, Ovarian Cancer
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00281632
- Testing
- GW786034
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer
Lung Cancer, Non-Small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
- Trial name
- CheckMate870 (NCT03195491)
- Testing
- Nivolumab
- Where
- 30 sites in China, Thailand
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
The study consists of a retrospective observational, multicenter study in which the fundamental exposure factor being investigated is a drug (rucaparib).
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04539327
- Testing
- Rucaparib
- Where
- 23 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Lung Cancer, Medication Adherence
Implementation Strategies for Monitoring Adherence in Real Time
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies.
- Conditions
- Lung Cancer, Medication Adherence, Symptoms and Signs
- Trial name
- iSMART (NCT04347161)
- Testing
- Conversational Agent/Chatbot, Usual Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic/Advanced Renal Cell Carcinoma
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center Principal assumption : the proportion of patients presenting…
- Trial name
- RENACALL (NCT02187042)
- Testing
- Best supportive care, call center
- Where
- 13 sites in France
- Volunteers
- 70 people
- Sponsor
- Pfizer
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00569673
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Where
- 37 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gynecologic Oncology Group
Carcinoma, Renal Cell, Kidney Disease
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
- Conditions
- Carcinoma, Renal Cell, Kidney Disease, Kidney Cancer
- Trial name
- NCT00854620
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02819024
- Testing
- Dexamethasone, Device for PET, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing…
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma
- Trial name
- NCT00093782
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a chemotherapy and radiotherapy sensitive tumor, but with very high rates of relapse and metastasis, resulting in a very poor outcome.
- Trial name
- NCT01173523
- Testing
- STA-9090
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- David M. Jackman, MD
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.